Los peligros de los anticonceptivos y su uso en la mujer transexual (página 2)

5. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.

6. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing a thirdgeneration progestagen. Lancet 1995; 346: 1593-6.

7. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk actors for upper extremity deep venous thrombosis.JThromb Haemost2005;3:2471-8.

8. Borrego L, Gil R, Mazuecos A. Cholesterol embolism to the skin. Clin Exp Dermatol 1992;17:424-6.

9. Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet 1973; i: 1399-404.

10. Dahlberg PJ, Frecentese DF, Cogbill TH. Cholesterol embolism: experience with 22 histologically proven cases. Surgery 1989; 105:737-46.

11. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.

12. De Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet 1998; 351:1404.

13. Del Río E, Vázquez Veiga H, Martín de Hijas C, Gorospe MA, Sánchez Yus E. Necrosis cutánea por embolización de cristales de colesterol. Actas Dermosifiliogr 1993;84:303-6..

14. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.Contraception 2007;75:344-54.

15. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005; 113:586-92.

16. Drife JO. The third generation pill controversy (continued). BMJ 2001; 323:119-20.

17. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.

18. Farmer RD, Todd JC, MacRae KD, Williams TJ, Lewis MA. Oral contraception was not associated with venous thromboembolic disease in recent study. Br Med J 1998; 316: 1090-1.

19. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987;38:769-84

20. Flory CM. Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Pathol 1945; 21: 549-64.

21. Futterweit W. Terapia de la transexualidad y las complicaciones potenciales. Archives of Sexual Behavior 1998; 27: 209-226

22. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight.Cochrane Database Syst Rev2008;(4):CD003987.

23. Garcia-Malpartida K, Martin-Gorgojo A, Rocha M, Gomez-Balaguer M, Hernandez-Mijares A. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertil Steril 2010;94:1097.e13-15

24. Giltay EJ, Gooren LJG. Effect of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21…

25. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005; 64(suppl 2):31-6.

26. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19-25.

27. Gooren LJG y Delemarre-van de Waal. Memo sobre la viabilidad de las intervenciones endocrinos en los transexuales de menores. Revista de Psicología y Sexualidad Humana 1996; 8: 69-74

28. Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors for non-fatal venous thromboembolism. Thromb Haemost 1998; 79: 28-31.

29. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7.

30. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75:328-36.

31. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354:127-8.

32. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.

33. Huisman MV, Buller HR, Ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314: 823-8.

34. Jick H, Derby LE, Wald Myers M, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopasusal oestrogens. Lancet 1996; 348: 981-3.

35. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in using oral contraceptives with differing progestagen .Lancet1995; 346:1589-93.

36. Jordan WM. Pulmonary embolism. Lancet 1961; i: 1146-7.

37. Kamphuisen PW, Eikenboom JCJ, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.

38. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323:131-4.

39. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.Thromb Haemost 2002; 87:199-205.

40. Konstantinides S. Acute pulmonary embolism. N Eng J Med. 2008;359:2804-13

41. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5

42. Kuhnz W, Staks T, Jutting G. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.Contraception 1993; 48:557-75.

43. Lachnit-Fixson U. The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen.Acta Obstet Gynecol Scand Suppl1979;88:33-42.

44. Lensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, Krekt J, Wouter TC, Huisman MV, Buller HR. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989; 320: 342-5.

45. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolim. A case-control study.Contraception 1998; 57:291-301.

46. Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev 2009;(2):CD006586.

47. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.

48. McNeill EJM. Management of the transgender voice. J Laryngol Otology 2006; 120:521-3.

49. Middeldorp S, Meijers JC, Van den Ende AE, Van Enk A, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84:4-8.

50. Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. Arch Intern Med 1996;156:653-7

51. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467- 73.

52. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.Ann N Y Acad Sci1995; 761: 311-35.

53. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study.J Thromb Haemost 2007; 5:692-9.

54. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid , drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.J Clin Endocrinol Metab1995;80:1816-21.

55. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3"-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.

56. Porter JB. Oral contraceptives and nonfatal vascular disease — recent experience. Obstet Gynecol 1982; 59: 299-302.

57. Prasad RN, Koh SC, Viegas OA, Ratnam SS. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Thromb Hemost 1999; 5:60-70.

58. Records Unit and Research Advisory Service of the Royal College of General Practioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 1967; 13: 267-79.

59. Revenga Arranz F, García Bracamonte B, Quintana Martínez I, Rodríguez Peralto JL, Iglesias Díez L. Embolismo de colesterol con afectación cutánea: presentación de tres casos. Actas Dermosifiliogr 1996;87:269-71

60. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-90.

61.  Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.

62. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis Thromb Haemost 2001; 86:112-23.

63. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.

64. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95:193-7.

65. Rosing J, Middeldorp S, Curvers J, Christela M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354:2036-40.

66. Rosing J, Tans G, Nicolaes GA, Thomanssen MC, Van der Oerle R, Van der Ploeg PM. Oral contraceptives and venous trombosis: different sensitivies to activated protein C in women using second-and third generation oral contraceptives. Br J Haematol 1997; 97:233-8.

67. Royal College of General Practioners" Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978; 28: 393-9.

68. Sánchez R, Martinez O. Guía práctica en anticoncepción oral basada en la evidencia. Madrid: Emisa, 2003.

69. Sapp AV, Lindbloom EJ. Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis? J Fam Pract 2001; 50:893.

70. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365-80.

71. Schlatterer K, Yassouiridis A, von Werder K, Polonia D, Kemper J, Stalla GK. Un estudio de seguimiento a la estimación de la eficacia de una terapia de sustitución hormonal de género cruzado en pacientes transexuales. Archives of Sexual Behavior, 1998; 27: 475-492…

72. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/ drospirenone and other oral contraceptives.Obstet Gynecol 2007; 110:587-93.

73. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83-8.

74. Spitzer WO. El acetato de ciproterona con etinilestradiol como un factor de riesgo de tromboembolismo venoso: una evaluación epidemiológica. J Obstet Gynaecol Can. 2003 Dec;25(12):1011-8.

75. Stegeman BH, deBastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298.

76. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197-208.

77. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84:15-21.

78. Tans G, van Hylckama Vlieg A, Thomassen MCLGD, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.Br J Haematol2003; 122:465-70.

79. The Coronary Drug Project Research Group. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973; 226: 652-7.

80. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52

81. Van Haarst EP, Newling ARD, Gooren LJG, Asscheman H, Prenger. DM metastásico carcinoma de próstata en un transexual de hombre a mujer. British Journal of Urology, 1998; 81: 776

82. Van Kesteren P, Lips P, Gooren LJG, Asscheman H, Megens J (1998) A largo plazo de seguimiento de la densidad mineral ósea en los transexuales tratados con hormonas del sexo opuesto. Clinical Endocrinology 48: 347-354

83. Van Kesteren P, Megens JAJ, Asscheman H, efectos. Gooren LJG secundarios de la administración hormonal del sexo en transexuales. Clinical Endocrinology, 1997; 47: 337-342

84. Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-42..

85. Van Vliet HA, Frolich M, Christella M, Thomassen MCLGD, Doggen CJM, Rosendaal FR, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.Hum Reprod 2005; 20:563-8.

86. Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.J Thromb Haemost 2004; 2:2060-2.

87. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.

88. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83.

89. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2: 199-205.

90. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. Br Med J 1969; 2: 651-7.

91. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346:1575-82.

92. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346:1582-8.

93. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Technical Report Series Geneva: WHO, 1998

94. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.

95. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary acid in transsexual persons. J Clin Endocrinol Metab 2008; 93:2230-3.